Evolut Low Risk研究两年随访结果解读  

An interpretation of the 2-year follow-up results of Evolut Low Risk research

作　　者：杨晧然 熊恬园[1] 陈茂[1] YANG Haoran;XIONG Tianyuan;CHEN Mao(Department of Cardiology,West China Hospital,Sichuan University,Chengdu,610041,P.R.China)

机构地区：[1]四川大学华西医院心脏内科,成都610041

出　　处：《中国胸心血管外科临床杂志》2021年第8期884-887,共4页Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

摘　　要：对于重度主动脉瓣狭窄患者,经导管主动脉瓣置换术(transcatheter aortic valve replacement,TAVR)已成为一种成熟的治疗方式,尤其是针对具有外科手术中、高风险的患者,TAVR均展示出了不劣于甚至优于外科主动脉瓣置换术(surgical aortic valve replacement,SAVR)的疗效,且5年随访结果稳定。但是对于外科手术低风险患者,TAVR与SAVR治疗对比的随机对照研究尚缺乏较长随访时间的结果。本文就Evolut Low Risk的研究概况、阶段性研究结果及其给主动脉瓣介入治疗带来的启示进行阐述。Transcatheter aortic valve replacement(TAVR)has become a well-established treatment for patients with severe aortic stenosis.At present,TAVR has already shown noninferiority and even superiority to surgical aortic valve replacement(SAVR)in patients deemed at high or intermediate risk for SAVR.However,the long-term follow-up results of the randomized controlled trials comparing the efficacy and safety between TAVR and SAVR are still lacking in those patients who are at low risk for SAVR.This paper gives an overview and reviews results of the Evolut Low Risk trial and interprets its implications for transcatheter therapy in aortic valve diseases.

关 键 词：主动脉瓣狭窄 经导管主动脉瓣置换术(TAVR) 低危 

分 类 号：R654.2[医药卫生—外科学]